Factor VII Inhibitor Profile, Comprehensive
Also known as: Bethesda Titer
Use
Confirmation and characterization of factor VII inhibitor
Special Instructions
Ensure that the patient is not anticoagulated before the test. Do not draw the sample from an arm with a heparin lock or heparinized catheter as it may affect the results.
Limitations
Residual coagulation factor activity could falsely lower the Bethesda titer result. Lupus anticoagulant activity and antithrombotic agents must be ruled out to avoid false positives. Some autoimmune inhibitors demonstrating second-order kinetics cannot always be accurately measured with the Bethesda titer system.
Methodology
Other
Biomarkers
LOINC Codes
- 5902-2
- 5959-2
- 33356-7
- 33884-8
- 14979-9
- 3198-9
- 3196-3
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
6 mL (2 mL in each of three tubes)
Minimum Volume
Not provided
Container
Blue-top (sodium citrate) tubes
Collection Instructions
Collect citrated plasma samples by double centrifugation using a blue-top tube containing 3.2% buffered sodium citrate. Ensure proper blood to anticoagulant ratio by filling the tube completely. Mix immediately by gentle inversion at least six times. A discard tube is not required unless using a winged blood collection device. After centrifugation, carefully remove plasma without disturbing cells, place in Labcorp PP transpak frozen purple tube with screw cap, and freeze immediately.
Patient Preparation
The patient should not be anticoagulated. Avoid drawing from an arm with a heparin lock or heparinized catheter.
Storage Instructions
Freeze immediately and maintain frozen until tested.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Stable at room temperature for four hours |
Other tests from different labs that may be relevant